- Home
- HLP vs KZIA Comparison
HLP vs KZIA Comparison
Compare HLP & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLP
- KZIA
- Stock Information
- Founded
- HLP 2021
- KZIA 1994
- Country
- HLP China
- KZIA Australia
- Employees
- HLP N/A
- KZIA N/A
- Industry
- HLP Industrial Machinery/Components
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- HLP Industrials
- KZIA Health Care
- Exchange
- HLP Nasdaq
- KZIA Nasdaq
- Market Cap
- HLP 15.5M
- KZIA 12.6M
- IPO Year
- HLP 2023
- KZIA 1999
- Fundamental
- Price
- HLP $1.13
- KZIA $4.57
- Analyst Decision
- HLP
- KZIA Strong Buy
- Analyst Count
- HLP 0
- KZIA 1
- Target Price
- HLP N/A
- KZIA $20.00
- AVG Volume (30 Days)
- HLP 14.1K
- KZIA 139.2K
- Earning Date
- HLP 11-26-2024
- KZIA 11-29-2024
- Dividend Yield
- HLP N/A
- KZIA N/A
- EPS Growth
- HLP N/A
- KZIA N/A
- EPS
- HLP N/A
- KZIA N/A
- Revenue
- HLP $14,045,084.00
- KZIA $1,663,331.00
- Revenue This Year
- HLP N/A
- KZIA $4,053,954.00
- Revenue Next Year
- HLP N/A
- KZIA N/A
- P/E Ratio
- HLP N/A
- KZIA N/A
- Revenue Growth
- HLP N/A
- KZIA 10739.13
- 52 Week Low
- HLP $0.72
- KZIA $1.90
- 52 Week High
- HLP $5.54
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- HLP 37.50
- KZIA 43.58
- Support Level
- HLP $1.10
- KZIA $5.63
- Resistance Level
- HLP $1.31
- KZIA $6.88
- Average True Range (ATR)
- HLP 0.09
- KZIA 0.83
- MACD
- HLP 0.00
- KZIA -0.16
- Stochastic Oscillator
- HLP 8.61
- KZIA 7.69
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll formed steel profile manufacturer in China. It customizes and manufactures cold roll formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture and transportation.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.